Nod for Ranbaxy Malaysia plan

Ranbaxy Malaysia Sdn Bhd, a wholly- owned subsidiary of Ranbaxy Labs, has got the Malaysian government’s approval for setting up a greenfield manufacturing plant in there.

Ranbaxy will be investing around RM 125 million ($40 Million) in this project and  will be Ranbaxy’s second facility in Malaysia.

“The setting up of a new facility reinforces our commitment to the Malaysian market. In addition to serving the local market the facility will also export products to markets like ASEAN, West Asia, Europe, Lanka, China,” said Arun Sawhney, CEO & MD, Ranbaxy.

The new plant would manufacture dosage forms primarily in the cardiovascular, anti diabetic, anti-infective and gastrointestinal segments. Its total output in Malaysia will be increased from 1 billion doses per annum to 3 billion doses per year when the new plant becomes fully operational.